🇺🇸 FDA
Pipeline program

177Lu-TLX250

177Lu-TLX250-302

Phase 3 other active

Quick answer

177Lu-TLX250 for ccRCC is a Phase 3 program (other) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Telix Pharmaceuticals Ltd
Indication
ccRCC
Phase
Phase 3
Modality
other
Status
active

Clinical trials